View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 17, 2022

AGC and RoosterBio partner for cell and exosome therapy manufacturing

RoosterBio will use its cell and media product portfolio to create scalable processes for hMSC and exosome therapies.

Biopharmaceutical contract development and manufacturing organisation (CDMO) AGC Biologics has entered a strategic collaboration with RoosterBio to expedite the manufacturing of cell and exosome therapies.

The alliance will merge the cell and media products and process development services of RoosterBio with the worldwide cell and gene therapy manufacturing expertise of AGC. 

This approach will aid in creating an end-to-end solution for developing and producing human mesenchymal stem/stromal cell (hMSC) and exosome therapies.

To create strong and scalable processes for hMSC and exosome therapies, RoosterBio will leverage its broad-ranging cell and media product portfolio.

These capabilities comprise cell and exosome genetic engineering for expressing therapeutic targets.

Other capabilities include upstream processing in 2D flask and 3D bioreactor systems, downstream purification for attaining preferred purity and potency, as well as complete analytical characterisation of the resultant cell or exosome therapy that is formulated. 

In order to offer complete process development, quality control and regulatory services, cGMP manufacturing for pre-clinical and Phase I/II clinical trials, AGC will use its worldwide network. 

It will also have the potential to scale to Phase III clinical development and commercial manufacturing. 

Furthermore, the CDMO provides various customisable development and manufacturing scales according to the requirements of drug developers in various regions globally. 

Its network of sites extends access to the newest cell therapy technologies and processes, including allogenic and autologous systems and methods.

RoosterBio CEO Tim Kelly said: “AGC Biologics has an outstanding track record of success in the manufacture of clinical and commercial advanced therapies and an ever-expanding global network to meet the needs of our customers. 

“This collaboration was conceived to deliver that end-to-end solution for our customers, and I am thrilled to partner with AGC Biologics to translate our hMSC and exosome technologies into advanced therapy products that have the potential to bring curative treatments to patients in need.”

In June 2020, AGC Biologics was selected by Novavax for large-scale production of an adjuvant for its Covid-19 vaccine candidate, NVX-CoV2373.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology